Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells

Rumi S. Bhattacharyya, Aruna V. Krishnan, Srilatha Swami, and David Feldman

Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, California

Abstract

The androgen receptor (AR) plays a key role in the development and progression of prostate cancer. Targeting the AR for down-regulation would be a useful strategy for treating prostate cancer, especially hormone-refractory or androgen-independent prostate cancer. In the present study, we showed that the antiestrogen fulvestrant [ICI 182,780 (ICI)] effectively suppressed AR expression in several human prostate cancer cells, including androgen-independent cells. In LNCaP cells, ICI (10 μmol/L) treatment decreased AR mRNA expression by 43% after 24 hours and AR protein expression by ~50% after 48 hours. We further examined the mechanism of AR down-regulation by ICI in LNCaP cells. ICI did not bind to the T877A-mutant AR present in the LNCaP cells nor did it promote proteasomal degradation of the AR. ICI did not affect AR mRNA or protein half-life. However, ICI decreased the activity of an AR promoter-luciferase reporter plasmid transfected into LNCaP cells, suggesting a direct repression of AR gene transcription. As a result of AR down-regulation by ICI, androgen induction of prostate-specific antigen mRNA and protein expression were substantially attenuated. Importantly, LNCaP cell proliferation was significantly inhibited by ICI treatment. Following 6 days of ICI treatment, a 70% growth inhibition was seen in androgen-stimulated LNCaP cells. These data show that the antiestrogen ICI is a potent AR down-regulator that causes significant inhibition of prostate cancer cell growth. Our study suggests that AR down-regulation by ICI would be an effective strategy for the treatment of all prostate cancer, especially AR-dependent androgen-independent prostate cancer. [Mol Cancer Ther 2006;5(6):1539–49]

Introduction

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the United States (1). For patients with localized prostate cancer, initial treatment includes surgery or radiation as a means of removing or destroying tumor cells localized within the prostate capsule (2, 3). For those men not cured by primary therapy, androgen deprivation therapy is often successful in causing cancer regression because these cancers almost always express androgen receptor (AR) and exhibit androgen-dependent growth (4). Unfortunately, most men eventually fail androgen deprivation therapy and their disease transforms from androgen-dependent to an androgen-independent prostate cancer (AIPC), progressing even in the presence of castrate levels of androgens (2–4). Currently, there is no therapy that successfully treats AIPC.

AR expression is retained in a significant proportion of AIPC (5, 6). Several mechanisms or pathways influence the development of AIPC, allowing the AR to stimulate proliferation even in the absence of androgens. These include the presence of (a) a “hypersensitive” AR often resulting from AR overexpression due to gene amplification or increased sensitivity to very low androgen levels, (b) a “promiscuous” AR harboring mutations in its ligand-binding domain that allow nonandrogen ligands to bind and activate the AR, and (c) an “outlaw” AR that is activated in a ligand-independent manner often through cross-talk with other signal transduction pathways (7). Regardless of the mechanisms underlying AIPC development, the AR seems to be a key protein involved in many cases of AR-dependent AIPC and is critical for promoting prostate cancer cell growth. Therefore, targeting the AR for down-regulation or degradation could be a useful approach for decreasing AR-dependent prostate cancer cell growth and for treating AIPC (8, 9).

Estrogens and androgens are known to exert opposing effects on each other’s actions in many tissues (10–12). Androgens and estrogens have also been shown to regulate the expression of each other’s receptors (12–15). We have shown in earlier studies that estrogens repress AR expression in human breast cancer cells (12). In the current study, we examined the possibility that estrogenic and antiestrogenic molecules down-regulate AR expression.
in prostate cancer cells. Of the compounds examined, the antiestrogen fulvestrant, also known as ICI 182,780 (ICI) or Faslodex, exhibited the most potent AR down-regulatory effect. ICI caused significant suppression of AR mRNA and protein expression, AR-mediated functional responses, and cell proliferation in LNCaP prostate cancer cells. Further studies carried out to unravel the mechanism of the down-regulation suggested that the ICI effect was due to a direct transcriptional repression of the AR gene.

Materials and Methods

Materials

ICI was purchased from Tocris Cookson, Inc. (Ellisville, MO). Tritiated 5α-dihydrotestosterone ([3H]DHT; specific activity 50 Ci/mmol) and tritiated 1α,25-dihydroxyvitamin D3 ([3H]-1,25(OH)2D3; specific activity 106 Ci/mmol) were purchased from Amersham Biosciences (Piscataway, NJ). The synthetic androgen methyltrienolone (R1881) was obtained from DuPont NEN Life Science Products (Boston, MA). Genestein, daidzein, raloxifene, tamoxifen, cycloheximide, and actinomycin D were purchased from Sigma-Aldrich (St. Louis, MO). 5α-DHT and 17β-estradiol (E2) were purchased from Steraloids, Inc. (Wilton, NH). LNCaP, T47D, and MCF-7 cells were obtained from the American Type Culture Collection (Manassas, VA). LAPC-4 cells were a gift from Dr. Charles Sawyer (University of California at Los Angeles, Los Angeles, CA). LN95 and LN97 cells were a generous gift from Dr. Joel Nelson (Johns Hopkins University, Baltimore, MD). 22Rv1 cells were established from a CWR22R xenograft by Sramkoski et al. (16) and were kindly provided by Dr. Zijie Sun (Stanford University, Stanford, CA). PS-341 was a gift from Millennium Pharmaceuticals (Cambridge, MA). Tissue culture media were from Mediatech (Herndon, VA). Antibiotics and fetal bovine serum (FBS) were from Invitrogen/Life Technologies (Carlsbad, CA). charcoal-stripped serum (CSS) was purchased from Fisher Scientific (Hampton, NH).

Cell Culture

LNCaP and T47D cells were cultured in RPMI 1640 supplemented with 5% FBS and penicillin (100 units/mL) and streptomycin (100 μg/mL). LAPC-4 cells were maintained in RPMI 1640 without phenol red supplemented with 10% FBS. MCF-7 cells were cultured in DMEM/F-12 medium supplemented with 10% FBS and penicillin (100 units/mL) and streptomycin (100 μg/mL). LN95 and LN97 cells were maintained in RPMI 1640 without phenol red supplemented with 10% CSS and penicillin (100 units/mL) and streptomycin (100 μg/mL). 22Rv1 cells were cultured in RPMI 1640 supplemented with 10% FBS, 10 mmol/L HEPES, 1.0 mmol/L sodium pyruvate, 4.5 g/L glucose, 100 units/mL penicillin, and 100 μg/mL streptomycin. All cells were routinely cultured in T-75 flasks at 37°C with 5% CO2 in a humidified incubator. For most experiments, the growth medium was replaced with phenol red–free RPMI 1640 supplemented with 5% CSS. Stock solutions of all test compounds were made in 100% ethanol and added to the treatment medium. All controls received ethanol vehicle at a concentration equal to that in the hormone-treated cells (0.1%, v/v).

Ligand-Binding Assays

Radioligand-binding assays were done using [3H]DHT (for measurement of AR) or [3H]-1,25(OH)2D3 [for measurement of vitamin D receptor (VDR)] as the ligand. Semi confluent cell cultures were treated for 24 to 72 hours with various estrogenic molecules or antiestrogens. Cells were harvested, washed, and pelleted. Cell extracts were prepared by sonication of the cell pellet in a high-salt buffer followed by high-speed centrifugation as described previously (17). Aliquots of cell extracts, which contained both nuclear and cytoplasmic proteins, were incubated overnight at 4°C with saturating concentrations of [3H]DHT (10 nmol/L) or [3H]-1,25(OH)2D3 (1 nmol/L). Nonspecific binding was assessed in parallel assays containing 250-fold excess radioinert DHT or 1,25(OH)2D3, respectively, and subtracted from total binding to yield specific binding. Specific binding is a quantitative assessment of functional AR or VDR. Protein concentrations were quantitated using the Bradford method (18). AR or VDR concentrations were expressed as femtomoles of ligand bound per milligram of protein.

Competition Analysis

Competition-binding experiments to assess the ability of the test compounds to bind to the T877A-mutant AR present in LNCaP cells were conducted as described previously (19). Briefly, high-salt extracts from LNCaP cells were incubated with [3H]DHT as the ligand and increasing concentrations (1–1,000 molar excess) of the test molecules as competitors.

Immunoblots

Aliquots of high-salt extracts prepared from cells treated with vehicle, estrogenic compounds, or antiestrogens (25–50 μg protein) were separated by NuPAGE gel electrophoresis (Invitrogen) and transferred to nitrocellulose membranes. Membranes were probed with specific primary antibodies against AR (N-20), estrogen receptor-α (ER-α; D-12), and actin (C-2, Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:1,000 dilution or anti α-tubulin (clone DM1A, NeoMarkers, Fremont, CA) at a 1:5,000 dilution in 5% Blotto solution (Santa Cruz Biotechnology). Either an anti-rabbit or an anti-mouse secondary antibody was used at a 1:2,000 dilution (Cell Signaling Technology, Beverly, MA). Chemiluminescence reagents (Cell Signaling Technology) were used to visualize immunoreactive protein bands. The blots were simultaneously probed for the expression of actin or α-tubulin as a loading control.

RNA Isolation, Reverse Transcription, and Real-time PCR

RNA was isolated from control or treated cells using the Trizol reagent (Invitrogen), and total cellular RNA (5 μg) was reverse transcribed using the SuperScript III synthesis system for reverse transcription-PCR (RT-PCR; Invitrogen). An aliquot of the reverse transcription product was...
amplified by real-time PCR using gene-specific primers and the DyNAmo SYBR Green PCR kit (New England Biolabs, Beverly, MA) using the Opticon 2 Real-time PCR Detection System (Bio-Rad Laboratories, Waltham, MA). Expression levels of mRNA for AR, prostate-specific antigen (PSA), TATA box-binding protein, and glyceraldehyde-3-phosphate dehydrogenase were measured using specific primers for each gene. The mRNA expression of TATA box-binding protein or glyceraldehyde-3-phosphate dehydrogenase was used as a control. AR primers were 5'-AGTCCTCAGCTGTTAAGGCA-3' (forward) and 5'-TCCTTTCCCTAGCG-3' (reverse). PSA primers were 5'-GCCAGTTGAACCAATGGGAGC-3' (forward) and 5'-CACCATTACAGCAAGTGGGC-3' (reverse). TATA box-binding protein primers were 5'-TGCTGAGAAGCATGTTGCGAG-3' (forward) and 5'-TCTGAAATAGGCTGTGGGTC-3' (reverse). Glyceraldehyde-3-phosphate dehydrogenase primers were 5'-AAATCCCATCACCA-3' (forward) and 5'-ACTTC-3' (reverse). Changes in gene expression were determined using the comparative C(TΔC(T) method as described (20).

PSA Assay
Conditioned media from control or treated LNCaP cells were collected and centrifuged at low speeds to remove cell debris. PSA concentrations in the conditioned media were determined using an ELISA kit (Diagnostic Systems Laboratories, Webster, TX) according to the manufacturer's instructions.

Cell Proliferation Assay
LNCaP cells were seeded in six-well plates at a density of 3 x 10^5 per well in RPMI 1640 plus 5% FBS. After 24 hours, the cultures were treated with various agents in phenol red–free RPMI 1640 supplemented with 5% CSS for the next 6 days. Media containing the treatments were replenished after 3 days. Cell proliferation was assessed by determining the DNA content at the end of the experiment (21).

Transient Transfections and Luciferase Assays
LNCaP cells were seeded into six-well plates at a cell density of 3 x 10^5 per well in RPMI 1640 plus 5% FBS without antibiotics. Cells were allowed to attach for 24 hours before transfection of a plasmid containing an ~6-kb AR promoter linked to a luciferase reporter in the pGL3-Basic vector (a generous gift from Dr. Donald Tindall, Mayo Clinic, Rochester, MN). Transient transfections of the AR promoter-luciferase plasmid or the pGL3-Basic vector plasmid were carried out using LipofectAMINE (Invitrogen) for 18 hours. Cells were cotransfected with a renilla luciferase plasmid (Promega, Madison, WI) as a control for transfection efficiency. Following transfections, cells were treated with vehicle (0.1% ethanol) or ICI in RPMI 1640 plus 5% CSS. After 24 hours, cells were harvested and reporter and renilla luciferase activities were determined by the Dual-Luciferase Assay System (Promega).

Statistical Analysis
Statistical analysis was carried out using GraphPad Prism software (version 3.02) for Windows (GraphPad Software, San Diego, CA). Significance of results was determined by ANOVA and Newman-Keuls’ post-test or Student’s t test as appropriate. P < 0.05 was considered significant.

Results
AR Down-Regulation by ICI
We examined the effect of several estrogenic molecules and antiestrogens on AR expression in LNCaP human prostate cancer cells. These compounds included E2, the phytoestrogens genistein and daidzein, selective ER modulators, such as tamoxifen and raloxifene, and the antiestrogen ICI. All of the compounds examined, with the exception of genistein, exhibited significant decreases in AR levels as measured by [3H]DHT binding after a 48-hour treatment (Fig. 1A). The antiestrogen ICI (10 μmol/L) was the most effective in reducing AR expression in LNCaP cells, decreasing AR to 56% of control levels after 48 hours of treatment. Significant AR down-regulation was also seen after treatment with the phytoestrogen daidzein (67% of control) and the selective ER modulator raloxifene (66% of control). The effects of E2 (77% of control) and tamoxifen (75% of control) were more modest. In subsequent experiments, we focused on ICI as the most effective down-regulator of AR expression.

Because the AR in LNCaP cells has a mutation in its ligand-binding domain, we determined whether ICI had any effects on cell lines harboring the wild-type AR, such as LAPC-4 human prostate cancer cells and T47D breast cancer cells. In both the LAPC-4 and T47D cells, ICI (10 μmol/L) elicited smaller but statistically significant decreases (15–25% inhibition) in [3H]DHT binding (Fig. 1B), showing that ICI down-regulated the expression of both mutant and wild-type AR. We also examined the effects of ICI on AR expression in AIPC cells, such as 22Rv1, LN95, and LN97. The 22Rv1 cell line was established from the CWR22R human prostate cancer xenograft, which was serially propagated in mice after castration-induced regression and relapse of the parental androgen-dependent CWR22 xenograft (16). 22Rv1 cells represent an androgen-independent but androgen-responsive cell line (16, 22). We also used the LN95 and LN97 androgen-independent human prostate cancer cells. These cells are LNCaP sublines that were established by culturing LNCaP cells under androgen-deprived conditions for prolonged periods. These LNCaP sublines can readily form tumors in both castrate and intact male athymic nu/nu mice (23). In all three cell lines examined, ICI (10 μmol/L) decreased [3H]DHT binding after 48 hours of treatment (20–25% inhibition; Fig. 1B). We also found ~30% decrease in AR mRNA levels in 22Rv1 cells following ICI treatment for 6 to 24 hours (data not shown). These results suggest that ICI decreases AR expression in both androgen-dependent and AIPC cells.

Because the antiestrogen ICI is known to down-regulate ER levels (24) and we showed down-regulation of AR, we wished to determine whether ICI modulated the expression of a number of genes.
of other nuclear receptors as well. We examined the ICI effect on VDR levels in LNCaP cells. ICI treatment of LNCaP cells for 48 h did not significantly change VDR levels as measured by \( ^{[3}H\)-1,25(OH)\(_2\)D\(_3\) binding (control VDR levels, 9.87 \pm 2.9 \text{fmol/mg}; ICI-treated VDR levels, 9.98 \pm 1.7 \text{fmol/mg}). These data suggest that the ICI-mediated down-regulation is not a general effect on all nuclear receptors.

**Time Course and Dose Response of AR Protein Down-Regulation**

The effect of ICI on AR protein expression was determined by both \( ^{[3}H\)-DHT binding and Western blot analysis using an anti-AR antibody (Santa Cruz Biotechnology). Time course experiments in LNCaP cells showed that ICI (10 \( \mu \text{mol/L} \)) decreased \( ^{[3}H\)-DHT binding by 41% after 24 hours of treatment (Fig. 2A). Maximal inhibition (52%) was seen at 48 hours, and the inhibitory effect persisted up to 72 hours. Western blot analysis revealed similar decreases in AR immunoreactive bands at 24, 48, and 72 hours following ICI treatment (Fig. 2B). Densitometric analysis of the Western blot shown in Fig. 2B showed that the decreases in AR protein seen at the various time points agreed with the results of the ligand-binding data (an \( \sim 50\% \) decrease in AR/actin expression compared with control at each time point). Dose-response studies showed that ICI at 5 and 10 \( \mu \text{mol/L} \) significantly decreased \( ^{[3}H\)-DHT binding by 20\% and 50\% of control, respectively (Fig. 2C). Higher concentrations of ICI (100 \( \mu \text{mol/L} \)) did not further down-regulate AR levels. We also examined the effects of ICI on AR protein expression under androgen-replete conditions in the presence of medium supplemented with FBS. After 48 hours, ICI (10 \( \mu \text{mol/L} \)) inhibited \( ^{[3}H\)-DHT binding by 55\% of control (Fig. 2D). These responses are similar to the effects of ICI observed under androgen-depleted conditions (CSS; Fig. 2A).

**Lack of ICI Effect on AR Protein Degradation**

Previous studies on the effects of ICI on ER have shown that ICI binds to the ER and prevents estrogen signaling, thereby acting as an antiestrogen (24). At the same time, by binding to the ER, ICI decreases the stability of the ER-\( \alpha \) protein and promotes ER-\( \alpha \) degradation by the proteasome (25, 26). The AR expressed in LNCaP cells contains a point mutation (T877A) in its ligand-binding domain that relaxes its specificity and allows nonandrogenic ligands to bind to and activate the receptor (27). Several nonandrogenic steroids, such as progestins and glucocorticoids, as well as various estrogenic molecules have been shown to bind to the T877A-mutant AR (28, 29). Therefore, we examined whether ICI could bind to the T877A-mutant AR in LNCaP cells and thereby promote AR protein degradation in a manner similar to its effects on the ER. Competition-binding assays were done in nuclear extracts of LNCaP cells using \( ^{[3}H\)-DHT as the ligand and increasing concentrations of radioinert DHT, E\(_2\), and ICI as competitors. Unlike radioinert DHT and E\(_2\), increasing concentrations of ICI up to a 1,000-fold excess of \( ^{[3}H\)-DHT did not displace \( ^{[3}H\)-DHT bound to the AR, showing that ICI did not bind to the mutant AR (Fig. 3A).

We examined the effect of the proteasomal inhibitor PS-341 (bortezomib, Velcade) on AR down-regulation by ICI (30). The ICI effect on ER-\( \alpha \) protein degradation in MCF-7 breast cancer cells was assessed in parallel assays as a positive control. LNCaP or MCF-7 cells were treated with ICI (10 \( \mu \text{mol/L} \)) in the presence or absence of PS-341 (100 \( \text{nmol/L} \)) for 24 to 48 hours. High-salt cellular extracts were made, and AR and ER-\( \alpha \) protein expression were determined by Western blot analysis. Immunoreactive ER-\( \alpha \) protein was decreased after 24 hours of ICI treatment in MCF-7 cells (Fig. 3B). As expected in the presence of the proteasomal inhibitor PS-341, the down-regulation of ER-\( \alpha \) by ICI was abolished. PS-341 treatment by itself caused a
slight decrease in AR protein in LNCaP cells (Fig. 3B). Cotreatment with PS-341 did not prevent the decrease in AR protein levels elicited by ICI, suggesting the lack of involvement of the proteasomal pathway in AR down-regulation by ICI.

We also determined whether ICI treatment altered AR protein half-life ($t_{1/2}$). After 24 hours of 0.1% ethanol vehicle (control) or 10 μmol/L ICI treatment, LNCaP cells were treated with the protein synthesis inhibitor cycloheximide at 2.5 μg/mL. Cells were harvested at 2-hour intervals following cycloheximide treatment, and AR protein expression was examined by Western blotting analysis (Fig. 3C). ICI treatment did not significantly change AR protein $t_{1/2}$, suggesting that ICI does not have any post-translational effects on AR down-regulation.

Inhibition of AR mRNA Expression and AR Transcription by ICI

We examined the effects of ICI on AR mRNA expression by using real-time RT-PCR analysis. Time course experiments showed that AR mRNA expression in LNCaP cells was decreased by 34% as early as 4 hours after ICI (10 μmol/L) treatment (Fig. 4A). These inhibitory effects persisted after 6 and 24 hours of ICI treatment, producing a 40% to 45% decrease in AR mRNA expression. By 48 hours of ICI treatment, the down-regulatory effects of ICI subsided. In parallel, we measured VDR mRNA expression after ICI treatment and no significant changes in VDR mRNA were apparent (data not shown), suggesting the selectivity of the down-regulatory effects of ICI on AR mRNA.

We carried out the following experiments to distinguish between transcriptional and post-transcriptional effects of ICI. LNCaP cells were treated with 10 μmol/L ICI in the presence and absence of various concentrations (up to 1 μg/mL) of the protein synthesis inhibitor cycloheximide, and AR mRNA levels were measured. Figure 4B illustrates the lack of an effect of 0.25 μg/mL cycloheximide on ICI down-regulation of AR mRNA, showing that new protein synthesis was not required for the suppression of AR mRNA by ICI.

Figure 4C shows the effect of ICI on AR mRNA $t_{1/2}$. LNCaP cells were treated with vehicle or ICI (10 μmol/L). After 24 hours of ICI treatment, the transcriptional inhibitor actinomycin D (4 μmol/L) was added to the cultures. Cells were harvested at 2-hour intervals (following the addition of actinomycin D), and AR mRNA levels were measured by real-time RT-PCR. Our results suggest that ICI did not significantly change AR mRNA $t_{1/2}$.

The time course of AR mRNA repression by ICI showed that the effect was seen as early as 4 hours (Fig. 4A). This fact, coupled with the lack of change in mRNA $t_{1/2}$, suggests that ICI may be directly repressing the AR gene at
the transcriptional level. To determine whether ICI acted directly on the AR promoter to inhibit AR gene transcription, we examined the effect of ICI on the activity of an AR promoter-reporter construct transfected into LNCaP cells. LNCaP cells were transiently transfected with a plasmid containing an ~6-kb AR promoter fragment linked to a luciferase reporter plasmid. A renilla luciferase plasmid (pRL) was used as a control for transfection efficiency. Transfected cells were treated with either vehicle or ICI (10 μmol/L) for 24 hours, and reporter and renilla luciferase activities were measured. ICI treatment significantly decreased AR promoter-luciferase activity compared with vehicle treatment (Fig. 4D).

**Inhibition of AR-Mediated Functional Responses by ICI**

We next assessed whether the decrease in AR levels due to ICI treatment would result in the attenuation of AR-mediated functional responses in LNCaP cells. The effect of ICI on androgen-induced PSA mRNA expression and PSA secretion was determined. LNCaP cells were treated with ICI (10 μmol/L) in the presence or absence of the synthetic androgen R1881. R1881 (0.1–10 nmol/L) substantially induced PSA mRNA expression in LNCaP cells (Fig. 5A). Cotreatment with ICI totally abolished the induction of PSA mRNA seen at 0.1 nmol/L R1881 and restored the values to control levels. ICI partially reversed the induction seen at higher concentrations (1 and 10 nmol/L) of R1881 (~20% inhibition). ICI treatment alone seemed to slightly decrease basal PSA mRNA expression.

We also examined the effect of ICI on basal as well as androgen-stimulated secretion of PSA protein (Fig. 5B). LNCaP cells were treated for 6 days with 0.1% ethanol vehicle or 0.1 nmol/L R1881 with and without ICI (1–10 μmol/L) cotreatment. Conditioned media from treated cells were collected during the last 3 days of treatment, and PSA concentrations were determined by an ELISA. Treatment with 0.1 nmol/L R1881 resulted in an ~3-fold increase in the levels of secreted PSA. ICI dose dependently inhibited androgen-stimulated PSA secretion. The lowest concentration of ICI (1 μmol/L) elicited a 55% inhibition in the R1881-stimulated PSA secretion, and the highest concentration of ICI examined (10 μmol/L) decreased PSA secretion by 90% (Fig. 5B). As shown in Fig. 5C, ICI treatment alone decreased basal PSA secretion to almost undetectable levels. A higher concentration of R1881 (10 nmol/L) caused a much more substantial increase (~25-fold over control) in secreted PSA, which was significantly decreased (to ~5-fold over control) by ICI cotreatment (Fig. 5C).

**Inhibition of Androgen-Stimulated LNCaP Cell Proliferation by ICI**

We next examined the ability of ICI to decrease androgen stimulation of LNCaP cell proliferation. LNCaP cells were cultured for 6 days in CSS medium containing various concentrations of ICI (1–50 μmol/L). ICI at 1 μmol/L significantly decreased basal cell proliferation by 32% (Fig. 6A). This inhibitory effect of ICI was maximal at 10 μmol/L, producing a 48% inhibition in cell growth, an effect that was not further increased by 50 μmol/L ICI (42% inhibition). The ICI effect was also examined in LNCaP cells stimulated with R1881. LNCaP cells were cultured for 6 days in medium containing 5% CSS treated with R1881 (0.1 nmol/L) in the presence or absence of ICI (10 μmol/L; Fig. 6B). R1881 at a low concentration of 0.1 nmol/L stimulated the proliferation of LNCaP cells. ICI (10 μmol/L) alone significantly inhibited basal LNCaP cell proliferation. ICI also significantly
attenuated R1881-stimulated growth by \( \sim 70\% \) (Fig. 6B). Western blotting analysis confirmed that AR expression remained suppressed following 6 days of ICI treatment. The blots were simultaneously probed with either actin or \( \alpha \)-tubulin as the loading control. In this experiment shown in Figure 6B, the actin levels showed variations at the end of 6-day hormone treatments. Therefore, we used \( \alpha \)-tubulin to normalize the data.

Additionally, we compared the growth-inhibitory effects of ICI with the antiandrogen Casodex (bicalutamide). LNCaP cells were treated for 6 days with ICI (10 \( \mu \)mol/L) or Casodex (1–10 \( \mu \)mol/L) in the presence or absence of 0.1 nmol/L R1881 (Fig. 6C). Both ICI and Casodex suppressed androgen stimulation of cell growth. The degree of inhibition of R1881-stimulated cell proliferation by ICI was comparable with that of 10 \( \mu \)mol/L Casodex at the end of 6 days of treatment. A lower concentration of Casodex (1 \( \mu \)mol/L) exhibited lesser inhibitory effects on androgen-stimulated cell proliferation. AR protein expression was again significantly decreased following ICI treatment for 6 days.

Discussion

A significant proportion of AIPC exhibits AR expression (31, 32), and some AIPC patients express up to 70-fold higher levels of AR mRNA and increased AR protein compared with primary prostate cancer patients (31, 33). In a recent study by Chen et al. (32), AR mRNA was found to be universally up-regulated in all of the hormone-refractory prostate cancer (AIPC) models that were examined. Because the AR is clearly a critical factor in prostate cancer and AIPC development, down-regulating or reducing the AR would be a very useful strategy for treating AR-dependent prostate cancer (8). Thus far, the techniques that have been used to down-regulate the AR include antisense oligonucleotides (34, 35), ribozyme treatments (36, 37), AR dominant negatives (38), and small interfering RNAs (39–41). Reducing AR levels by these various means results in the inhibition of prostate cancer cell growth and PSA expression, while the small interfering RNA knockdown of AR expression also leads to significant apoptotic cell death in androgen-sensitive and AIPC cells (39–41). Various studies have shown that estrogens have the ability...
to down-regulate AR expression in different target cells (12, 14, 42). In particular, studies from our laboratory have shown that MCF-7 breast cancer cells treated with E2 exhibited significantly lower levels of AR (12). The current study examined the effect of estrogenic compounds and antiestrogens on AR expression in prostate cancer cells. In our study, the order of potencies for AR down-regulation was ICI > daidzein > raloxifene > tamoxifen > E2. The selective ER modulators tamoxifen and raloxifene have been shown to cause apoptosis of prostate cancer cells (43, 44). Zeng et al. (45) showed that raloxifene treatment of probasin/SV40 T antigen transgenic rats caused significant inhibition of prostate carcinogenesis and was associated with decreased AR expression in the ventral prostate. Although genistein has been shown to decrease AR levels in prostate cancer cells (46), we did not find an appreciable change in AR concentration following genistein treatment. Our study is the first to show the ICI effect to down-regulate AR in prostate cancer cells. In addition to LNCaP cells, ICI-mediated down-regulation was also seen in cells that express wild-type AR, such as the LAPC-4 prostate cancer and the T47D breast cancer cells. Furthermore, AIPC cells, such as the LNCaP sublines LN95 and LN97 as well as 22Rv1, also responded to ICI with AR down-regulation, suggesting that ICI might be therapeutically useful in AIPC. Importantly, we also showed that ICI significantly decreased both androgen-stimulated cell proliferation and PSA expression in LNCaP cells. ICI is a potent antiestrogen that binds to the ER with high affinity (47) and impairs both ER dimerization (48) and nucleocytoplasmic shuttling (49). ICI binding to ER-α leads to decreased ER-α stability and increased turnover of the ER-α protein through enhanced proteasomal degradation (25, 26). Because the mutant AR in LNCaP cells binds to estrogenic compounds (27), it was possible that ICI could bind to the mutant AR and enhance its proteasomal degradation in a manner similar to its effect on ER-α. However, our data indicated that ICI did not bind to the mutant T877A AR (Fig. 3A), did not promote AR degradation through the proteasomal pathway (Fig. 3B), and did not change AR protein $t_{1/2}$ (Fig. 3C). The down-regulation of AR mRNA by ICI was not prevented by the addition of the protein synthesis inhibitor cycloheximide, indicating that new protein synthesis was not required (Fig. 4B). AR mRNA $t_{1/2}$ was also not altered by ICI treatment (Fig. 4C). Taken together, these data suggest that the ICI down-regulation of AR is not at a post-transcriptional level. We further showed that ICI directly suppressed the activity of an AR promoter-luciferase construct transfected into LNCaP cells (Fig. 4D). These data indicate that ICI down-regulation is due to a direct transcriptional repression of the AR gene. The exact mechanism of the transcriptional repression of AR by ICI has yet to be defined. The effect of ICI on AR transcription might be mediated through the ER. LNCaP cells have been shown to express ER-β (50, 51). We have detected ER-β protein and mRNA expression in LNCaP cells, whereas ER-α protein was undetectable (data not shown).
shown). It is therefore possible that ICI suppresses AR transcription by acting through ER-β via one or more estrogen response elements present in the AR promoter. An initial computer analysis of the AR promoter has revealed several potential estrogen response element sites. Although ICI down-regulates ER-α expression, ER-β protein is not always similarly degraded after ICI treatment (52, 53). Several studies have examined the role of ER-β in the regulation of AR and prostate cancer cell proliferation by other estrogenic molecules. Bektic et al. (46) have shown that AR down-regulation by genistein in LNCaP cells is mediated through ER-β. ER-β also plays an important role in the induction of LNCaP cell proliferation by 5α-DHT and E2 (54). However, very recently, Taylor et al. (55) showed that estradiol down-regulates AR protein expression in the ventral prostate of both ER-α and ER-β knockout mice, arguing against a role for ER-α or ER-β in the down-regulation of AR. ICI is also capable of acting through progesterone response elements in the promoters of target genes (56). Further experiments need to be done to fully elucidate the mechanism of AR transcriptional repression by ICI.

Our data further showed that, as a consequence of down-regulating AR expression, ICI inhibited AR-mediated functional responses. Androgen stimulation of PSA mRNA expression and PSA protein secretion were both decreased by ICI in LNCaP cells (Fig. 5). Recent studies by Kawashima et al. (57) showed that ICI decreased DHT stimulation of the androgen-responsive mouse mammary tumor virus-luciferase reporter in LNCaP cells. ER ligands, including ICI, have been shown to inhibit DHT stimulation of PSA transcriptional activity in PC-3 and DU145 cells cotransfected with AR and ER-α and ER-β expression plasmids (58). Similarly, we have found that ICI inhibited R1881-mediated stimulation of a PSA-luciferase reporter plasmid transfected into LNCaP cells (data not shown). Importantly, ICI caused a significant inhibition of cell proliferation. Androgens exert a biphasic effect on LNCaP cell growth with low concentrations (<0.1 nmol/L) exhibiting growth stimulation, whereas higher concentrations inhibit growth (59). ICI completely blocked the growth stimulation seen with 0.1 nmol/L R1881 (Fig. 6B). The AR is critical for prostate cancer cell growth, and cell proliferation is significantly decreased in prostate cancer cells where AR expression has been decreased or disrupted (39–41). In our study, ICI also caused significant growth

Figure 6. Inhibition of androgen-stimulated LNCaP cell proliferation by ICI. LNCaP cells were seeded in six-well plates at $3 \times 10^5$ per well in RPMI 1640 + 5% FBS. A, after 24 h, cells were treated with 0.1% ethanol (control) or various concentrations of ICI (1–50 μmol/L) in RPMI 1640 + 5% CSS. Fresh media and reagents were replenished on day 4. After 6 d of treatment, cell proliferation was measured by assaying the DNA content in the well. B, LNCaP cells were seeded and cultured as in A. The treatments were control = 0.1% ethanol vehicle, 10 μmol/L ICI, 0.1 nmol/L R1881 (R18), or both (R1881 + ICI). DNA content was measured after 6 d of treatment. Inset, AR and α-tubulin protein expression as determined by Western blot analysis (see Materials and Methods). C, LNCaP cells were seeded and cultured as in A. The treatments were control = 0.1% ethanol vehicle, 10 μmol/L ICI, 1 and 10 μmol/L Casodex (Cdx), all in the presence (black columns) or absence (white columns) of 0.1 nmol/L R1881. DNA content was measured after 6 d of treatment. Inset, AR and actin protein expression as determined by Western blot analysis (see Materials and Methods). B and C, representative blots. Columns, mean of three determinations; bars, SE. *, $P < 0.05$ versus control; **, $P < 0.01$ versus control; ***, $P < 0.001$ versus control; +++, $P < 0.001$ versus R1881; *, $P < 0.05$ versus Casodex (1 μmol/L) + R1881.
inhibition under basal conditions possibly due to a blockade of the stimulatory effect of residual androgens present in the CSS. However, other mechanisms, in addition to AR down-regulation, may also be contributing to the inhibition of cell growth by ICI. Lau et al. (50) showed growth-inhibitory effects of ICI on both PC-3 and DU145 prostate cancer cells that do not express AR. Their study concluded that the decrease in cell growth generated by ICI was mediated through ER-β. It is probable that multiple mechanisms are involved in the growth-inhibitory effects of ICI, including regulation of other signaling pathways (60). However, based on our data and that of others (34–41), we believe that the down-regulation of the AR plays an important role in the growth-inhibitory action of ICI.

AIPC is a lethal form of prostate cancer, and effective treatment options have yet to be established. We hypothesize that reducing AR concentration will be a useful therapeutic strategy in all cases of prostate cancer but especially in AIPC. ICI (fulvestrant) is a drug currently used to treat women with ER-positive metastatic breast cancer. ICI is relatively safe and well tolerated by women with advanced breast cancer. Our findings suggest that ICI may present a useful treatment option for patients with AR-dependent prostate cancer. Unlike the ribozyme, antisense, small interfering RNA, or dominant-negative techniques, ICI, as an already approved drug, can be rapidly moved to clinical trials in prostate cancer patients. Unlike the ribozyme, antisense, small interfering RNA, or dominant-negative techniques, ICI, as an already approved drug, can be rapidly moved to clinical trials in prostate cancer patients.

A therapy that down-regulates the AR in AR-dependent AIPC would be particularly beneficial at a time in the course of prostate cancer, where effective therapies are currently not available.

Acknowledgments

We thank Dr. Donald Tindall for the AR promoter-luciferase reporter plasmid, Dr. Charles Sawyers for the LAPC4 prostate cancer cells, Dr. Joel Nelson for the LNCaP and LNCaP cells, and Millennium Pharmaceuticals for the PS-341 (borzertom, Velcade).

References

Molecular Cancer Therapeutics

Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells

Rumi S. Bhattacharyya, Aruna V. Krishnan, Srilatha Swami, et al.

*Mol Cancer Ther* 2006;5:1539-1549.

Updated version Access the most recent version of this article at:
http://mct.aacrjournals.org/content/5/6/1539

Cited articles This article cites 58 articles, 18 of which you can access for free at:
http://mct.aacrjournals.org/content/5/6/1539.full.html#ref-list-1

Citing articles This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/5/6/1539.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.